Elizabeth A. Chlipala

1.7k total citations
37 papers, 1.3k citations indexed

About

Elizabeth A. Chlipala is a scholar working on Molecular Biology, Immunology and Oncology. According to data from OpenAlex, Elizabeth A. Chlipala has authored 37 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 8 papers in Immunology and 7 papers in Oncology. Recurrent topics in Elizabeth A. Chlipala's work include AI in cancer detection (5 papers), Rheumatoid Arthritis Research and Therapies (5 papers) and Immunotherapy and Immune Responses (4 papers). Elizabeth A. Chlipala is often cited by papers focused on AI in cancer detection (5 papers), Rheumatoid Arthritis Research and Therapies (5 papers) and Immunotherapy and Immune Responses (4 papers). Elizabeth A. Chlipala collaborates with scholars based in United States, United Kingdom and Canada. Elizabeth A. Chlipala's co-authors include Alison M. Bendele, Gina Sennello, George N. Cox, Daniel H. Doherty, Mary S. Rosendahl, Darin Smith, Sharon J. Carlson, Jennifer McComb, Michael S. Guy and Dorothy McCabe and has published in prestigious journals such as PLoS ONE, Endocrinology and Pharmaceutical Research.

In The Last Decade

Elizabeth A. Chlipala

36 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Elizabeth A. Chlipala United States 22 470 307 252 239 232 37 1.3k
Thomas Kalinski Germany 30 1.0k 2.1× 544 1.8× 151 0.6× 316 1.3× 325 1.4× 113 2.6k
Robert Plenge United States 11 337 0.7× 306 1.0× 268 1.1× 471 2.0× 64 0.3× 17 1.3k
Anthony D. Kang United States 14 565 1.2× 353 1.1× 70 0.3× 172 0.7× 536 2.3× 18 1.7k
Yaqin Li China 24 1.1k 2.4× 321 1.0× 91 0.4× 221 0.9× 45 0.2× 160 2.0k
Bernd Bonnekoh Germany 24 634 1.3× 313 1.0× 109 0.4× 546 2.3× 71 0.3× 96 1.8k
Hidetoshi Kawashima Japan 26 317 0.7× 74 0.2× 328 1.3× 268 1.1× 575 2.5× 132 2.3k
Lisha Mou China 26 799 1.7× 121 0.4× 60 0.2× 254 1.1× 120 0.5× 132 1.8k
Dominique de Seny Belgium 25 938 2.0× 207 0.7× 807 3.2× 208 0.9× 69 0.3× 56 2.2k
Dan Liu China 19 221 0.5× 168 0.5× 32 0.1× 135 0.6× 241 1.0× 74 1.1k

Countries citing papers authored by Elizabeth A. Chlipala

Since Specialization
Citations

This map shows the geographic impact of Elizabeth A. Chlipala's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elizabeth A. Chlipala with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elizabeth A. Chlipala more than expected).

Fields of papers citing papers by Elizabeth A. Chlipala

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elizabeth A. Chlipala. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elizabeth A. Chlipala. The network helps show where Elizabeth A. Chlipala may publish in the future.

Co-authorship network of co-authors of Elizabeth A. Chlipala

This figure shows the co-authorship network connecting the top 25 collaborators of Elizabeth A. Chlipala. A scholar is included among the top collaborators of Elizabeth A. Chlipala based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elizabeth A. Chlipala. Elizabeth A. Chlipala is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Dietrich, W. Dalton, et al.. (2025). 3,3′-Diindolylmethane improves pathology and neurological outcome following traumatic brain injury. Neurotherapeutics. 22(2). e00531–e00531. 2 indexed citations
2.
Benton, Hilary P., et al.. (2025). Utilizing image analysis by optical density to evaluate changes in hematoxylin and eosin staining quality after reagent overuse. Journal of Histotechnology. 48(3). 123–134. 1 indexed citations
3.
Evans, Andrew, Richard W. Brown, Marilyn M. Bui, et al.. (2021). Validating Whole Slide Imaging Systems for Diagnostic Purposes in Pathology. Archives of Pathology & Laboratory Medicine. 146(4). 440–450. 111 indexed citations
4.
Chlipala, Elizabeth A., et al.. (2020). Optical density-based image analysis method for the evaluation of hematoxylin and eosin staining precision. Journal of Histotechnology. 43(1). 29–37. 27 indexed citations
5.
6.
Chlipala, Elizabeth A., Kathleen Dwyer, David Krull, et al.. (2019). National Society for Histotechnology and Digital Pathology Association Online Self-Paced Digital Pathology Certificate of Completion Program. Journal of Pathology Informatics. 10(1). 14–14. 1 indexed citations
7.
Ellsworth, Jeff L., Jacinthe Gingras, Hillard Rubin, et al.. (2019). Clade F AAVHSCs cross the blood brain barrier and transduce the central nervous system in addition to peripheral tissues following intravenous administration in nonhuman primates. PLoS ONE. 14(11). e0225582–e0225582. 21 indexed citations
8.
Bui, Marilyn M., Michael Riben, Kimberly H. Allison, et al.. (2018). Quantitative Image Analysis of Human Epidermal Growth Factor Receptor 2 Immunohistochemistry for Breast Cancer: Guideline From the College of American Pathologists. Archives of Pathology & Laboratory Medicine. 143(10). 1180–1195. 59 indexed citations
9.
Bell, Todd M., Virginia Espina, Svetlana Senina, et al.. (2017). Rapamycin modulation of p70 S6 kinase signaling inhibits Rift Valley fever virus pathogenesis. Antiviral Research. 143. 162–175. 19 indexed citations
10.
Eisenberg, Stephen P., et al.. (2014). PEGylation Improves the Pharmacokinetic Properties and Ability of Interferon Gamma to Inhibit Growth of a Human Tumor Xenograft in Athymic Mice. Journal of Interferon & Cytokine Research. 34(10). 759–768. 16 indexed citations
11.
Cox, George N., Elizabeth A. Chlipala, Darin Smith, et al.. (2014). Hematopoietic Properties of Granulocyte Colony-Stimulating Factor/Immunoglobulin (G-CSF/IgG-Fc) Fusion Proteins in Normal and Neutropenic Rodents. PLoS ONE. 9(3). e91990–e91990. 21 indexed citations
12.
Eisenberg, Stephen P., et al.. (2013). Site-Specific PEGylation Enhances the Pharmacokinetic Properties and Antitumor Activity of Interferon Beta-1b. Journal of Interferon & Cytokine Research. 33(12). 769–777. 11 indexed citations
13.
Woessner, Richard, Brian Tunquist, Christine Lemieux, et al.. (2009). ARRY-520, a novel KSP inhibitor with potent activity in hematological and taxane-resistant tumor models.. PubMed. 29(11). 4373–80. 51 indexed citations
14.
15.
Doherty, Daniel H., Stephen P. Eisenberg, Darin Smith, et al.. (2006). Design of homogeneous, monopegylated erythropoietin analogs with preserved in vitro bioactivity. Experimental Hematology. 34(6). 697–704. 33 indexed citations
16.
Rosendahl, Mary S., Daniel H. Doherty, Darin Smith, et al.. (2005). A Long-Acting, Highly Potent Interferon α-2 Conjugate Created Using Site-Specific PEGylation. Bioconjugate Chemistry. 16(1). 200–207. 86 indexed citations
17.
Cox, George N., Darin Smith, Sharon J. Carlson, et al.. (2004). Enhanced circulating half-life and hematopoietic properties of a human granulocyte colony-stimulating factor/immunoglobulin fusion protein. Experimental Hematology. 32(5). 441–449. 37 indexed citations
18.
Bendele, Alison M., et al.. (1999). Animal Models of Arthritis: Relevance to Human Disease. Toxicologic Pathology. 27(1). 134–142. 222 indexed citations
19.
Bendele, A.M., et al.. (1999). Effects of interleukin 1 receptor antagonist alone and in combination with methotrexate in adjuvant arthritic rats.. PubMed. 26(6). 1225–9. 23 indexed citations
20.
Bendele, Alison M., et al.. (1998). Effects of Interleukin-1 Receptor Antagonist in a Slow-Release Hylan Vehicle on Rat Type II Collagen Arthritis. Pharmaceutical Research. 15(10). 1557–1561. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Thomas Kalinski Breakdown of academic impact, for papers by Robert Plenge Breakdown of academic impact, for papers by Anthony D. Kang Breakdown of academic impact, for papers by Yaqin Li Breakdown of academic impact, for papers by Bernd Bonnekoh Breakdown of academic impact, for papers by Hidetoshi Kawashima Breakdown of academic impact, for papers by Lisha Mou Breakdown of academic impact, for papers by Dominique de Seny Breakdown of academic impact, for papers by Dan Liu
Rankless by CCL
2026